@Davisite are you able to expand a bit on how these AML mouse models could typically be expected to translate into human application?
For example, in the first graph (MOLM-13-luc), median survival went from 18 days (vehicle) to 30 days for the Bisantrene+Decitabine combination, with the single agents falling somewhere in between. Are these models far more aggressive in causing death in mice than in humans?
For the Bis+Dec combination to be a "major winner", what sort of effect would we be looking to see in human testing? I'm assuming it would be more than a 12 day increase in median survival as was seen in the mouse model.
Thanks in advance.
@Davisite are you able to expand a bit on how these AML mouse...
-
- There are more pages in this discussion • 58 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.87 |
Change
-0.155(7.67%) |
Mkt cap ! $317.5M | |||
| Open | High | Low | Value | Volume |
| $2.03 | $2.08 | $1.86 | $706.9K | 357.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2637 | $1.87 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.87 | 577 | 1 |
View Market Depth
| Last trade - 16.10pm 20/06/2024 (20 minute delay) ? |
| RAC (ASX) Chart |